NasdaqGM:NRIXBiotechs
How Weaker Q1 Results And Advancing Bexobrutideg Trials At Nurix Therapeutics (NRIX) Have Changed Its Investment Story
Nurix Therapeutics, Inc. reported first-quarter 2026 results with revenue of US$6.25 million versus US$18.45 million a year earlier, alongside a wider net loss of US$87.17 million and a basic loss per share of US$0.79 from continuing operations.
At the same time, Nurix highlighted progress in its targeted protein degradation pipeline, including patient enrollment in the Phase 2 DAYBreak CLL-201 trial for bexobrutideg and plans for a global Phase 3 confirmatory study to support potential...